Ulrich Alfons Müller
6PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Feb 25, 2023
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms.Dilvin Semo, Julius Obergassel, Marc Dorenkamp
|Feb 06, 2021
Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2.Maximilian Hopf, Christof Kloos, Gunter Wolf
|Sep 19, 2020
Long-term outcome of persons with diabetic and non-diabetic neuro-osteoarthropathy after foot correction using external fixation.A M S Spraul, A M Schönbach, N Müller
|Apr 09, 2019
Correction to: Agonistic autoantibodies against adrenergic receptors correlating with antihypertensive therapy in long-standing diabetes type 2.Christoph Werner, Nicolle Müller, Ulrich Alfons Müller
|Feb 17, 2019
Agonistic autoantibodies against B2-adrenergic receptors correlating with macrovascular disease in longstanding diabetes type 2.Christoph Werner, Nicolle Müller, Ulrich Alfons Müller
|Jan 20, 2018
Agonistic autoantibodies against adrenergic receptors correlating with antihypertensive therapy in long-standing diabetes type 2.Christoph Werner, Nicolle Müller, Ulrich Alfons Müller
Pageof 1
